title: The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study.
abstract: BACKGROUND
  Disease Activity Score in 28 Joints (DAS28) is a scoring system to evaluate disease activity and treatment response in rheumatoid arthritis (RA). A DAS28 score of greater than 3.2 is a well-described limit for treatment intensification; however, the reliability of DAS28 might be overestimated.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the reliability of DAS28 in RA, especially focusing on a subgroup of patients with a DAS28 score of greater than 3.2.
  
  
  METHODS
  Data from RA patients registered in the local part of Danish DANBIO Registry were collected in May 2015. Patients were categorized into 2 groups: First, those with DAS28 >3.2 with at least one swollen joint (SJ) or elevated C-reactive protein (CRP) ("objective group"), and second, patients with a DAS28 >3.2 who had no SJ, and CRP values were within the reference range ("subjective group"). Disease Activity Score in 28 Joints, Clinical Disease Activity Index, and Health Assessment Questionnaire scores were calculated for each group. We defined new score, DAS28 subjective, to focus on subjective parameters.
  
  
  RESULTS
  Two hundred thirty patients were included; 198 (86.1%) and 32 (13.9%) patients were in the objective and subjective groups, respectively. Patients in the subjective group had lower mean values of DAS28 (P < 0.001) and Evaluator Global Assessment (P < 0.001) with less common immunoglobulin M rheumatoid factor (P < 0.001) and anti-cyclic citrullinated peptide positivity (P = 0.02) and contrarily higher mean values of tender joints (P = 0.04) and DAS28 based on subjective parameters (P = 0.003) compared with the objective group.
  
  
  CONCLUSIONS
  Rheumatoid arthritis scoring systems should be used cautiously in patients who are considered for treatment intensification. Patients with central sensitization and psychological problems and those with false-positive diagnosis of RA are at high risk of overtreatment.
authors.affiliation: From the *Department of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg; and †Faculty of Health Sciences, University of Southern Denmark, Odense; ‡DANBIO Registry, Copenhagen; and §Department of Technology and Innovation, University of Southern Denmark, Odense, Denmark.
authors.forename: Inger Marie
authors.initials: IM
authors.lastname: Jensen Hansen
authors.forename: Rikke
authors.initials: R
authors.lastname: Asmussen Andreasen
authors.forename: Mark Nam
authors.initials: MN
authors.lastname: van Bui Hansen
authors.forename: Amir
authors.initials: A
authors.lastname: Emamifar
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D018771:Arthralgia / Q000175:diagnosis*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D002097:C-Reactive Protein / Q000032:analysis*; D003430:Cross-Sectional Studies; D003718:Denmark / Q000453:epidemiology; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D007158:Immunologic Techniques / Q000379:methods; D008297:Male; D054539:Medication Therapy Management / Q000458:organization & administration; D008875:Middle Aged; D062072:Patient Acuity; D015203:Reproducibility of Results; D012107:Research Design; D063189:Symptom Assessment / Q000379:methods / Q000592:standards
chemical_list: D018501:Antirheumatic Agents; D002097:C-Reactive Protein